2024
Lower Microscopy Sensitivity with Decreasing Malaria Prevalence in the Urban Amazon Region, Brazil, 2018–2021 - Volume 30, Number 9—September 2024 - Emerging Infectious Diseases journal - CDC
Rodrigues P, Johansen I, Ladeia W, Esquivel F, Corder R, Tonini J, Calil P, Fernandes A, Fontoura P, Cavasini C, Vinetz J, Castro M, Ferreira M. Lower Microscopy Sensitivity with Decreasing Malaria Prevalence in the Urban Amazon Region, Brazil, 2018–2021 - Volume 30, Number 9—September 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1884-1894. PMID: 39174028, PMCID: PMC11346994, DOI: 10.3201/eid3009.240378.Peer-Reviewed Original ResearchConceptsEffectiveness of malaria controlDecreasing malaria prevalenceEpidemiology of malariaPoint-of-care microscopyThreshold of microscopyPlasmodium vivaxMalaria prevalenceMalarial infectionMalaria controlMalaria transmissionP. falciparumMicroscopy sensitivityParasite densityAsymptomatic infectionRoutine surveillanceMalariaPrevalence surveyInfectionPrevalenceParasite genotypesTransmission hotspotsElimination strategiesRural residentsMolecular methodsCDC
2022
Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota
Petrone ME, Rothman JE, Breban MI, Ott IM, Russell A, Lasek-Nesselquist E, Badr H, Kelly K, Omerza G, Renzette N, Watkins AE, Kalinich CC, Alpert T, Brito AF, Earnest R, Tikhonova IR, Castaldi C, Kelly JP, Shudt M, Plitnick J, Schneider E, Murphy S, Neal C, Laszlo E, Altajar A, Pearson C, Muyombwe A, Downing R, Razeq J, Niccolai L, Wilson MS, Anderson ML, Wang J, Liu C, Hui P, Mane S, Taylor BP, Hanage WP, Landry ML, Peaper DR, Bilguvar K, Fauver JR, Vogels CBF, Gardner LM, Pitzer VE, St. George K, Adams MD, Grubaugh ND. Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota. Communications Biology 2022, 5: 439. PMID: 35545661, PMCID: PMC9095641, DOI: 10.1038/s42003-022-03347-3.Peer-Reviewed Original ResearchPopulation-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research
Kunst N, Stout N, O’Brien G, Christensen K, McMahon P, Wu A, Diller L, Yeh J. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. Journal Of The National Cancer Institute 2022, 114: 722-731. PMID: 35043946, PMCID: PMC9086756, DOI: 10.1093/jnci/djac013.Peer-Reviewed Original ResearchConceptsUsual careClinical benefitTP53 variantsIncremental cost-effectiveness ratioPathogenic TP53 variantsCancer-related deathGermline TP53 variantsUS birth cohortPotential health outcomesCost-effectiveness ratioIdentification of childrenTumor surveillanceClinical studiesRhabdomyosarcoma casesPediatric cancerEarly cancer detectionRoutine surveillanceBirth cohortHealth outcomesAge 20Newborn screeningMalignancy detectionFurther researchCareTP53
2018
Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators
Bates J, Parzynski CS, Dhruva SS, Coppi A, Kuntz R, Li S, Marinac‐Dabic D, Masoudi FA, Shaw RE, Warner F, Krumholz HM, Ross JS. Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators. Pharmacoepidemiology And Drug Safety 2018, 27: 848-856. PMID: 29896873, PMCID: PMC6436550, DOI: 10.1002/pds.4565.Peer-Reviewed Original ResearchConceptsAdverse event ratesSafety differencesEvent ratesMedical device utilizationICD utilizationRate ratioNational Cardiovascular Data RegistryICD modelsImplantable cardioverter defibrillatorEvent rate ratioMost patientsCardioverter defibrillatorProportion of individualsAmerican CollegeData registryRoutine surveillanceSample size estimatesAverage event rateDevice utilizationSignificance levelDifferencesPatientsRegistryDefibrillatorICD
2014
Cost-utility analysis of routine surveillance imaging of patients in first remission after treatment for diffuse large B-cell lymphoma.
Huntington S, Svoboda J, Doshi J. Cost-utility analysis of routine surveillance imaging of patients in first remission after treatment for diffuse large B-cell lymphoma. Journal Of Clinical Oncology 2014, 32: 6526-6526. DOI: 10.1200/jco.2014.32.15_suppl.6526.Peer-Reviewed Original Research
2008
Are Survey-Based Estimates of the Burden of Drug Resistant TB Too Low? Insight from a Simulation Study
Cohen T, Colijn C, Finklea B, Wright A, Zignol M, Pym A, Murray M. Are Survey-Based Estimates of the Burden of Drug Resistant TB Too Low? Insight from a Simulation Study. PLOS ONE 2008, 3: e2363. PMID: 18523659, PMCID: PMC2408555, DOI: 10.1371/journal.pone.0002363.Peer-Reviewed Original ResearchConceptsResistant tuberculosisIncident casesTotal burdenDrug-resistant TBDrug-resistant tuberculosisSecond-line antibioticsDrug treatment regimensDrug sensitivity testingDrug-resistant strainsBurden of resistanceEmergence of tuberculosisResistant TBTreatment regimensPrevalent casesWorldwide burdenIntroduction of interventionsRoutine surveillanceSurveillance strategiesDrug resistanceTuberculosisLaboratory capacityMycobacterium tuberculosisSensitivity testingTuberculosis modelBurden
1987
Routine surveillance for infections in nursing homes: Experience at two facilities
Vlahov D, Tenney J, Cervino K, Shamer D. Routine surveillance for infections in nursing homes: Experience at two facilities. American Journal Of Infection Control 1987, 15: 47-53. PMID: 3646856, DOI: 10.1016/0196-6553(87)90001-0.Peer-Reviewed Original ResearchConceptsNursing homesRoutine surveillanceEye infectionsGastrointestinal tractSpecial infection control measuresRespiratory tract infectionsInfection Surveillance ProgramInfection control measuresMaryland nursing homesInfection control programTract infectionsInfection definitionsIndividual patientsInfection controlInfectionSurveillance dataSurveillance programTractSurveillanceControl programsControl measuresHomePatientsPhysicians
1983
CHANGES IN MALARIA INCIDENCE AFTER MASS DRUG ADMINISTRATION IN NICARAGUA
Garfield R, Vermund S. CHANGES IN MALARIA INCIDENCE AFTER MASS DRUG ADMINISTRATION IN NICARAGUA. The Lancet 1983, 322: 500-503. PMID: 6136655, DOI: 10.1016/s0140-6736(83)90523-8.Peer-Reviewed Original ResearchConceptsMass drug administrationP falciparum infectionHigh transmission periodAnti-malaria campaignsApparent preventionPrimaquine dosesFalciparum infectionP vivaxP falciparumIncidence rateVivax casesMalaria casesAnti-malarial activityPlasmodium vivaxRoutine surveillanceDrug AdministrationMalaria incidencePositive resultsVivaxAdministrationExtrinsic cycleInfectionLimited effectIncidenceDoses
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply